RU2014112348A - Способ детекции нуклеосом, содержащих гистоновые варианты - Google Patents
Способ детекции нуклеосом, содержащих гистоновые варианты Download PDFInfo
- Publication number
- RU2014112348A RU2014112348A RU2014112348/15A RU2014112348A RU2014112348A RU 2014112348 A RU2014112348 A RU 2014112348A RU 2014112348/15 A RU2014112348/15 A RU 2014112348/15A RU 2014112348 A RU2014112348 A RU 2014112348A RU 2014112348 A RU2014112348 A RU 2014112348A
- Authority
- RU
- Russia
- Prior art keywords
- histone
- isoform
- variant
- sample
- nucleosomes
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 20
- 108010033040 Histones Proteins 0.000 claims abstract 92
- 108010047956 Nucleosomes Proteins 0.000 claims abstract 48
- 210000001623 nucleosome Anatomy 0.000 claims abstract 48
- 102000001708 Protein Isoforms Human genes 0.000 claims abstract 47
- 108010029485 Protein Isoforms Proteins 0.000 claims abstract 47
- 239000011230 binding agent Substances 0.000 claims abstract 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract 6
- 201000011510 cancer Diseases 0.000 claims abstract 6
- 239000000090 biomarker Substances 0.000 claims abstract 5
- 210000004369 blood Anatomy 0.000 claims abstract 4
- 239000008280 blood Substances 0.000 claims abstract 4
- 210000001072 colon Anatomy 0.000 claims abstract 4
- 210000004072 lung Anatomy 0.000 claims abstract 4
- 210000000214 mouth Anatomy 0.000 claims abstract 4
- 210000000496 pancreas Anatomy 0.000 claims abstract 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 2
- 208000011231 Crohn disease Diseases 0.000 claims abstract 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract 2
- 210000000481 breast Anatomy 0.000 claims abstract 2
- 210000003679 cervix uteri Anatomy 0.000 claims abstract 2
- 206010009887 colitis Diseases 0.000 claims abstract 2
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract 2
- 238000003745 diagnosis Methods 0.000 claims abstract 2
- 210000003238 esophagus Anatomy 0.000 claims abstract 2
- 210000003734 kidney Anatomy 0.000 claims abstract 2
- 210000001672 ovary Anatomy 0.000 claims abstract 2
- 210000002307 prostate Anatomy 0.000 claims abstract 2
- 210000000664 rectum Anatomy 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 210000003491 skin Anatomy 0.000 claims abstract 2
- 210000002784 stomach Anatomy 0.000 claims abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract 2
- 239000013060 biological fluid Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 108010077544 Chromatin Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000003483 chromatin Anatomy 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530304P | 2011-09-01 | 2011-09-01 | |
| US61/530,304 | 2011-09-01 | ||
| GBGB1115098.4A GB201115098D0 (en) | 2011-09-01 | 2011-09-01 | Method for detecting nucleosomes containing histone variants |
| GB1115098.4 | 2011-09-01 | ||
| PCT/GB2012/052131 WO2013030579A1 (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing histone variants |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018101257A Division RU2716494C2 (ru) | 2011-09-01 | 2012-08-31 | Способ детекции нуклеосом, содержащих гистоновые варианты |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014112348A true RU2014112348A (ru) | 2015-10-10 |
Family
ID=44882049
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014112348/15A RU2014112348A (ru) | 2011-09-01 | 2012-08-31 | Способ детекции нуклеосом, содержащих гистоновые варианты |
| RU2018101257A RU2716494C2 (ru) | 2011-09-01 | 2012-08-31 | Способ детекции нуклеосом, содержащих гистоновые варианты |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018101257A RU2716494C2 (ru) | 2011-09-01 | 2012-08-31 | Способ детекции нуклеосом, содержащих гистоновые варианты |
Country Status (20)
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115098D0 (en) | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
| GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| US9605313B2 (en) | 2012-03-02 | 2017-03-28 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10087485B2 (en) | 2012-06-06 | 2018-10-02 | The Trustees Of Princeton University | DNA barcoding of designer mononucleosome and chromatin array libraries for the profiling of chromatin readers, writers, erasers, and modulators thereof |
| EP3597774A1 (en) | 2013-03-13 | 2020-01-22 | Sequenom, Inc. | Primers for dna methylation analysis |
| EP3736344A1 (en) | 2014-03-13 | 2020-11-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3213084B2 (en) | 2014-10-29 | 2023-12-13 | Belgian Volition SPRL | Method for the enrichment of circulating tumor dna |
| EP3256858B1 (en) * | 2015-02-10 | 2020-03-25 | B.R.A.H.M.S GmbH | Histone h4 peptide as a biomarker |
| GB201511512D0 (en) * | 2015-07-01 | 2015-08-12 | Singapore Volition Pte Ltd | Use of cell-free nucleosomes as biomarkers |
| GB201511542D0 (en) * | 2015-07-01 | 2015-08-12 | Singapore Volition Pte Ltd | Use of cell free nucleosomes as biomarkers |
| GB201518665D0 (en) | 2015-10-21 | 2015-12-02 | Singapore Volition Pte Ltd | Method for enrichment of cell free nucleosomes |
| GB201518674D0 (en) | 2015-10-21 | 2015-12-02 | Singapore Volition Pte Ltd | Method for detecting nuleosomes containing histone modifications and variants |
| GB201604806D0 (en) * | 2016-03-22 | 2016-05-04 | Singapore Volition Pte Ltd | Method of identifying a cancer of unknown origin |
| GB201612815D0 (en) * | 2016-07-25 | 2016-09-07 | Belgian Volition Sa | Novel combination test |
| TWI726009B (zh) * | 2016-11-28 | 2021-05-01 | 比利時商比利時意志有限公司 | 用親和純化法分析生物樣品中源自腫瘤之無細胞核小體、分離生物樣品中純化之腫瘤dna、檢測生物樣品中源自腫瘤之核小體表觀遺傳表位或在動物或人類受試者中檢測癌症之方法或包括組蛋白h1結合劑之套組之用途 |
| KR20190104030A (ko) | 2016-12-09 | 2019-09-05 | 더 브로드 인스티튜트, 인코퍼레이티드 | Crispr 이펙터 시스템 기반 진단 |
| AU2018234832A1 (en) | 2017-03-15 | 2019-10-10 | Massachusetts Institute Of Technology | CRISPR effector system based diagnostics for virus detection |
| GB201721569D0 (en) | 2017-12-21 | 2018-02-07 | Belgian Volition Sprl | Method for the detection and treatment of colorectal adenomas |
| CA3087362A1 (en) | 2018-01-29 | 2019-08-01 | The Broad Institute, Inc. | Crispr effector system based diagnostics |
| FI4215621T3 (fi) | 2018-03-01 | 2025-07-28 | Epicypher Inc | Nukleosomimodifikaatioiden kvantifiointi kemiallisesti määriteltyjä rekombinanttinukleosomeja käyttämällä |
| CN112236520B (zh) | 2018-04-02 | 2025-01-24 | 格里尔公司 | 甲基化标记和标靶甲基化探针板 |
| CA3111887A1 (en) | 2018-09-27 | 2020-04-02 | Grail, Inc. | Methylation markers and targeted methylation probe panel |
| GB201818965D0 (en) | 2018-11-21 | 2019-01-09 | Belgian Volition Sprl | Method for the detection of colorectal cancer |
| GB201818963D0 (en) | 2018-11-21 | 2019-01-09 | Belgian Volition Sprl | Methof for the detection of prostate cancer |
| GB201906199D0 (en) | 2019-05-02 | 2019-06-19 | Belgian Volition Sprl | Method for the detection of cancer |
| GB201906201D0 (en) | 2019-05-02 | 2019-06-19 | Belgian Voltion Sprl | Method for the detection of protate cancer |
| GB201912251D0 (en) | 2019-08-27 | 2019-10-09 | Belgian Volition Sprl | Method of isolating circulating nucleosomes |
| KR20220111246A (ko) | 2019-08-27 | 2022-08-09 | 벨지언 볼리션 에스알엘 | 순환 뉴클레오솜을 단리하는 방법 |
| PL4070111T3 (pl) | 2019-12-02 | 2025-02-03 | Belgian Volition Srl | Zastosowanie wolnych pozakomórkowych nukleosomsów jako biomarkerów |
| BR112022018792A2 (pt) | 2020-03-20 | 2022-11-01 | Belgian Volition Srl | Método de triagem usando níveis de nucleossomos livres de células |
| JP2023544112A (ja) | 2020-09-21 | 2023-10-20 | ベルジアン ボリション エスアールエル | 血液中の遊離ヌクレオソームのインラインモニタリングのための装置 |
| TW202238131A (zh) | 2020-11-25 | 2022-10-01 | 比利時商比利時意志有限公司 | 測量無細胞核蛋白染色質片段之方法 |
| TW202238132A (zh) | 2020-12-08 | 2022-10-01 | 比利時商比利時意志有限公司 | 多發性硬化症之診斷方法 |
| TW202242130A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 循環轉錄因子分析 |
| TW202242145A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析 |
| TW202242146A (zh) | 2021-01-13 | 2022-11-01 | 比利時商比利時意志有限公司 | 肺癌的檢測方法 |
| GB202108185D0 (en) | 2021-06-08 | 2021-07-21 | Belgian Volition Sprl | Standardisation of nucleosome assays using biologically derived calibrants |
| GB202108452D0 (en) | 2021-06-14 | 2021-07-28 | Belgian Volition Sprl | Triaging method using cell free nucleosome levels |
| WO2023073179A1 (en) | 2021-10-29 | 2023-05-04 | Belgian Volition Srl | Homogeneous immunoassay method |
| GB202117799D0 (en) | 2021-12-09 | 2022-01-26 | Belgian Volition Srl | Method for the detection of blood cancer |
| WO2023170298A1 (en) | 2022-03-11 | 2023-09-14 | Belgian Volition Srl | Differential diagnosis method |
| GB202205212D0 (en) | 2022-04-08 | 2022-05-25 | Belgian Volition Sprl | Method for transplant organ health assessment |
| CA3265699A1 (en) | 2022-08-25 | 2024-02-29 | Belgian Volition Srl | METHOD FOR DETECTING DEMENTIA |
| EP4577833A1 (en) | 2022-08-25 | 2025-07-02 | Belgian Volition SRL | Method for measuring cell free chromatin |
| EP4639165A1 (en) | 2022-12-19 | 2025-10-29 | Belgian Volition SRL | Assessment of biological samples for nucleic acid analysis |
| EP4639173A1 (en) | 2022-12-19 | 2025-10-29 | Belgian Volition SRL | Calibration |
| GB202300607D0 (en) | 2023-01-16 | 2023-03-01 | Belgian Volition Srl | Proteins and methods for isolating circulating nucleosomes |
| GB202303562D0 (en) | 2023-03-10 | 2023-04-26 | Belgian Volition Sprl | Sample collection for liquid biopsy |
| WO2024213795A1 (en) | 2023-04-14 | 2024-10-17 | Belgian Volition Srl | Diagnosis method using cell free nucleosome levels |
| WO2024223947A1 (en) | 2023-04-28 | 2024-10-31 | Belgian Volition Srl | Use of cell free nucleosomes as biomarkers of carcinomas |
| GB202307768D0 (en) | 2023-05-24 | 2023-07-05 | Belgian Volition Srl | Use of cell free nucleosomes as biomarkers |
| GB202310137D0 (en) | 2023-07-03 | 2023-08-16 | Belgian Volition Srl | Method for the detection of cancer |
| WO2025012440A1 (en) | 2023-07-13 | 2025-01-16 | Belgian Volition Srl | Method for detection of the potential of a body fluid sample to produce extracellular traps |
| WO2025061853A1 (en) | 2023-09-19 | 2025-03-27 | Belgian Volition Srl | Lateral flow test device |
| WO2025093747A1 (en) | 2023-11-02 | 2025-05-08 | Belgian Volition Srl | Novel rapid high-throughput method of netosis induction and inhibition with physiologically relevant molecules |
| WO2025181348A1 (en) | 2024-03-01 | 2025-09-04 | Belgian Volition Srl | Method for determining the origin of circulating dna |
| WO2025253002A1 (en) | 2024-06-07 | 2025-12-11 | Belgian Volition Srl | Sample collection for liquid biopsy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4276843B2 (ja) * | 2001-03-23 | 2009-06-10 | 芳之 金井 | モノヌクレオソーム及びその製造方法、ヌクレオソームに特異的な抗体の測定方法、自己免疫病診断方法、ヌクレオソームｄｎａ製造方法、ｄｎａプレート、ｄｎａプレート製造方法、並びに抗ｄｎａ抗体測定法 |
| US20040186274A1 (en) | 2001-07-03 | 2004-09-23 | Allis C. David | Methylation of histone h4 at arginine 3 |
| DE10207735A1 (de) * | 2002-02-15 | 2003-08-28 | Euroimmun Gmbh | Verfahren zur Herstellung einer Nukleosomen-Präparation und deren Verwendung zur in vitro-Diagnose von Lupus erythematodes disseminatus (LED) |
| EP1483415A4 (en) * | 2002-02-20 | 2006-02-01 | Univ Virginia | NON-INVASIVE DIAGNOSTIC TEST USING HISTONE MODIFICATION MARKERS |
| GB0319376D0 (en) * | 2003-08-18 | 2003-09-17 | Chroma Therapeutics Ltd | Histone modification detection |
| WO2005040814A1 (en) * | 2003-10-14 | 2005-05-06 | Cancer Research Technology Limited | Methods and means of cancer detection by histone modification |
| EP1907856A2 (en) * | 2005-07-27 | 2008-04-09 | Oncomethylome Sciences SA | Angiogenesis inhibition based upon icam 1 or junb expression levels |
| CA2621953A1 (en) * | 2005-09-09 | 2007-03-22 | University Of Iowa Research Foundation | Biomarkers associated with age-related macular degeneration |
| US20110312897A1 (en) * | 2008-09-17 | 2011-12-22 | The Rockefeller University | Cathepsin l proteolytically processes histone h3 during mouse embryonic stem cell differentiation |
| EP2270510A1 (en) * | 2009-07-02 | 2011-01-05 | EMBL (European Molecular Biology Laboratory) | Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms |
| GB201115098D0 (en) | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
-
2011
- 2011-09-01 GB GBGB1115098.4A patent/GB201115098D0/en not_active Ceased
-
2012
- 2012-08-31 SG SG10201601168QA patent/SG10201601168QA/en unknown
- 2012-08-31 EP EP17201723.8A patent/EP3301449B1/en active Active
- 2012-08-31 JP JP2014527738A patent/JP2014529405A/ja not_active Withdrawn
- 2012-08-31 HU HUE12762367A patent/HUE038517T2/hu unknown
- 2012-08-31 CN CN201280053594.1A patent/CN104053993A/zh active Pending
- 2012-08-31 SG SG11201400202SA patent/SG11201400202SA/en unknown
- 2012-08-31 CA CA2845994A patent/CA2845994C/en active Active
- 2012-08-31 AU AU2012300643A patent/AU2012300643B2/en active Active
- 2012-08-31 RU RU2014112348/15A patent/RU2014112348A/ru unknown
- 2012-08-31 DK DK12762367.6T patent/DK2751569T3/en active
- 2012-08-31 KR KR1020147008116A patent/KR102130855B1/ko active Active
- 2012-08-31 CN CN201711384538.7A patent/CN108107215A/zh active Pending
- 2012-08-31 HR HRP20180362TT patent/HRP20180362T1/hr unknown
- 2012-08-31 PL PL12762367T patent/PL2751569T3/pl unknown
- 2012-08-31 EP EP12762367.6A patent/EP2751569B1/en active Active
- 2012-08-31 BR BR112014004584-4A patent/BR112014004584B1/pt active IP Right Grant
- 2012-08-31 RU RU2018101257A patent/RU2716494C2/ru active
- 2012-08-31 ES ES12762367.6T patent/ES2662380T3/es active Active
- 2012-08-31 ES ES17201723T patent/ES2955475T3/es active Active
- 2012-08-31 PT PT127623676T patent/PT2751569T/pt unknown
- 2012-08-31 MX MX2014002444A patent/MX349561B/es active IP Right Grant
- 2012-08-31 US US14/239,779 patent/US9400276B2/en active Active
- 2012-08-31 WO PCT/GB2012/052131 patent/WO2013030579A1/en not_active Ceased
-
2014
- 2014-02-20 ZA ZA2014/01296A patent/ZA201401296B/en unknown
-
2016
- 2016-06-22 US US15/189,977 patent/US10184945B2/en active Active
-
2017
- 2017-08-02 JP JP2017149809A patent/JP6494703B2/ja active Active
-
2018
- 2018-12-14 US US16/221,411 patent/US20190120853A1/en not_active Abandoned
-
2020
- 2020-07-09 US US16/925,125 patent/US20200341006A1/en not_active Abandoned
-
2022
- 2022-12-06 US US18/076,005 patent/US20230116530A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014112348A (ru) | Способ детекции нуклеосом, содержащих гистоновые варианты | |
| JP2014529405A5 (cg-RX-API-DMAC7.html) | ||
| RU2014112350A (ru) | Способ детекции нуклеосом, содержащих нуклеотиды | |
| JP2017215338A5 (cg-RX-API-DMAC7.html) | ||
| Paul | Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult | |
| Wong et al. | Noninvasive biomarkers in NAFLD and NASH—current progress and future promise | |
| JP2018536849A5 (cg-RX-API-DMAC7.html) | ||
| Rockey | Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography | |
| Chon et al. | Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population | |
| Demir et al. | The relationship between the neutrophil–lymphocyte ratio and disease activity in patients with ulcerative colitis | |
| Castera | Noninvasive assessment of liver fibrosis | |
| Patel et al. | Diagnosis of liver fibrosis: present and future | |
| RU2016134839A (ru) | Биомаркер и способы для ранней диагностики болезни альцгеймера | |
| Wong et al. | Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe | |
| RU2010123921A (ru) | Раковый маркер и терапевтическая мишень | |
| Caviglia et al. | Noninvasive assessment of liver fibrosis: Key messages for clinicians | |
| JP2018529931A5 (cg-RX-API-DMAC7.html) | ||
| Albhaisi et al. | Applying non-invasive fibrosis measurements in NAFLD/NASH: progress to date | |
| WO2022014580A1 (ja) | 非アルコール性脂肪性肝疾患マーカー、非アルコール性脂肪性肝疾患を検出するための方法、それに用いる試薬及び分析用キット | |
| Ge et al. | Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis | |
| JP2008514209A5 (cg-RX-API-DMAC7.html) | ||
| Mjelle et al. | Ultrasound and point shear wave elastography in livers of patients with primary sclerosing cholangitis | |
| Lippi et al. | Diagnostics in venous thromboembolism: from origin to future prospects | |
| JP2019510974A5 (cg-RX-API-DMAC7.html) | ||
| JP2012526543A5 (cg-RX-API-DMAC7.html) |